1. Home
  2. CVAC vs RYAM Comparison

CVAC vs RYAM Comparison

Compare CVAC & RYAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVAC
  • RYAM
  • Stock Information
  • Founded
  • CVAC 2000
  • RYAM 1926
  • Country
  • CVAC Germany
  • RYAM United States
  • Employees
  • CVAC N/A
  • RYAM N/A
  • Industry
  • CVAC Biotechnology: Pharmaceutical Preparations
  • RYAM Paper
  • Sector
  • CVAC Health Care
  • RYAM Basic Materials
  • Exchange
  • CVAC Nasdaq
  • RYAM Nasdaq
  • Market Cap
  • CVAC 637.1M
  • RYAM 577.2M
  • IPO Year
  • CVAC 2020
  • RYAM N/A
  • Fundamental
  • Price
  • CVAC $2.54
  • RYAM $9.22
  • Analyst Decision
  • CVAC Hold
  • RYAM Buy
  • Analyst Count
  • CVAC 3
  • RYAM 1
  • Target Price
  • CVAC $10.00
  • RYAM $12.00
  • AVG Volume (30 Days)
  • CVAC 540.3K
  • RYAM 708.2K
  • Earning Date
  • CVAC 11-12-2024
  • RYAM 11-05-2024
  • Dividend Yield
  • CVAC N/A
  • RYAM N/A
  • EPS Growth
  • CVAC N/A
  • RYAM N/A
  • EPS
  • CVAC N/A
  • RYAM N/A
  • Revenue
  • CVAC $70,565,734.00
  • RYAM $1,630,290,000.00
  • Revenue This Year
  • CVAC $123.97
  • RYAM $0.53
  • Revenue Next Year
  • CVAC N/A
  • RYAM $2.60
  • P/E Ratio
  • CVAC N/A
  • RYAM N/A
  • Revenue Growth
  • CVAC 75.11
  • RYAM N/A
  • 52 Week Low
  • CVAC $2.22
  • RYAM $3.02
  • 52 Week High
  • CVAC $6.30
  • RYAM $10.28
  • Technical
  • Relative Strength Index (RSI)
  • CVAC 34.97
  • RYAM 58.23
  • Support Level
  • CVAC $2.73
  • RYAM $7.91
  • Resistance Level
  • CVAC $2.97
  • RYAM $10.28
  • Average True Range (ATR)
  • CVAC 0.18
  • RYAM 0.42
  • MACD
  • CVAC -0.01
  • RYAM 0.08
  • Stochastic Oscillator
  • CVAC 7.55
  • RYAM 57.06

About CVAC CureVac N.V.

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

About RYAM Rayonier Advanced Materials Inc.

Rayonier Advanced Materials Inc manufactures high-purity cellulose derived from wood. Also known as cellulose specialties, the company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, High-Yield Pulp, and Corporate and Other. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: